Immunogenicity of allo-vesicle carrying ErbB2 tumor antigen for dendritic cell-based anti-tumor immunotherapy

International Journal of Immunopathology and Pharmacology

Volumn 22, Issue 3, 2009, Pages 647-658

  Napoletano, C ^a   Rughetti, Aurelia ^a   Landi, R ^a   Pinto, D ^a   Bellati, F ^a   Rahimi, H ^a   Spinelli, G P ^a   Pauselli, S ^a   Sale, P ^a,b   Dolo, V ^c   De Lorenzo, F ^a   Tomao, F ^a   Benedetti Panici, P ^a   Frati, L ^a   Nuti, M ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Anti tumor immune response; Antigen presentation; Cancer immunotherapy; Cancer vaccine; Dendritic cells; ErbB2; Microvesicle

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CANCER THERAPY; CD8+ T LYMPHOCYTE; CELL VACUOLE; CONTROLLED STUDY; DENDRITIC CELL; EXOSOME; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOTHERAPY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; VACCINATION;

ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; DENDRITIC CELLS; FEMALE; HLA ANTIGENS; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; RECEPTOR, ERBB-2; TRANSFECTION; TRANSPORT VESICLES;

EID: 70350538868     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200902200310     Document Type: Article

References (32)

1. Gilboa E. DC-based cancer vaccines. J Clin Invest 2007; 117:1195-1203
2. Vulink A, Radford KJ, Melief C, Hart DN. Dendritic cells in cancer immunotherapy. Adv Cancer Res 2008; 99:363-407.
3. Pupa SM, Tagliabue E, Ménard S, Anichini A. HER-2: a biomarker at the crossroads of breast cancer immunotherapy and molecular medicine. J Cell Physiol 2005; 205:10-18 (Pubitemid 41262846)
4. Nanda R. Targeting the human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer: recent advances and future directions. Rev Recent Clin Trials 2007; 2:111-116 (Pubitemid 46773878)
5. Knutson KL, Disis ML, Expansion of HER2/neuspecific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine. Clin Breast Cancer 2001; 2:73-79
6. Peoples GE, Gurney JM, Hueman MT, et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol 2005; 23:7536-7545
7. Schorey JS, Bhatnagar S. Exosome function: from tumor immunology to pathogen biology. Traffic 2008; 9:871-881 (Pubitemid 351639493)
8. Andre F, Schartz NE, Movassagh M, et al. Malignant effusions and immunogenic tumour-derived exosomes. Lancet 2002; 360:295-305. (Pubitemid 34874721)
9. Wolfers J, Lozier A, Raposo G, et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 2001; 7: 297-303. (Pubitemid 32224344)
10. Yang Y, Xiu F, Cai Z, Wang J, Wang Q, Fu Y, Cao X. Increased induction of antitumor response by exosomes derived from interleukin-2 gene-modified tumor cells. J Cancer Res Clin Oncol 2007; 133:389-99. (Pubitemid 46716703)
11. Millimaggi D, Mari M, D'Ascenzo S, Carosa E, Jannini EA, Zucker S, Carta G, Pavan A, Dolo V. Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells. Neoplasia 2007; 9:349-357 (Pubitemid 46608302)
12. Valenti R, Huber V, Iero M, Filipazzi P, Parmiani G, Rivoltini L. Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res 2007; 67:2912-2915
13. Clayton A, Mitchell JP, Court J, Linnane S, Mason MD, Tabi Z. Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol 2008; 180:7249-7258
14. Clayton A, Mitchell JP, Court J, Mason MD, Tabi Z. Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. Cancer Res 2007; 67:7458-7466 (Pubitemid 47214451)
15. Mignon G, Roux S, Thery C, Ségura E, Zitvogel L. Prospects for exosomes in immunotherapy of cancer. J Cell Mol Med 2006; 10:376-388
16. Qazi KR, Gehrmann U, Domange Jordö E, Karlsson MC, Gabrielsson S. Antigen-loaded exosomes alone induce Th1-type memory through a B-cell-dependent mechanism. Blood 2009; 113:2673-2683
17. Andre F, Chaput N, Schartz NE, et al. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J Immunol 2004; 172:2126-2136
18. Lamparski HG, Metha-Damani A, Yao JY, Patel S, Hsu DH, Ruegg C, Le Pecq JB. Production and characterization of clinical grade exosomes derived from dendritic cells. J Immunol Methods 2002; 270:211-226
19. Escudier B, Dorval T, Chaput N, et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial. J Transi Med 2005; 3:10. (Pubitemid 40617869)
20. Ben-Bassat H, Goldblum N, Mitrani S, et al. Establishment in continuous culture of a new type of lymphocyte from a "Burkitt like" malignant lymphoma (line D.G.-75). Int J Cancer 1977; 19:27-33.
21. Tacken PJ, de Vries IJ, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007; 7:790-802. (Pubitemid 47480309)
22. Hao S, Bai O, Li F, Yuan J, Laferte S, Xiang J. Mature dendritic cells pulsed with exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumour immunity. Immunology 2007; 120:90-102. (Pubitemid 44950474)
23. Morelli AE, Larregina AT, Shufesky WJ, et al. Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells. Blood 2004; 104:3257-3266
24. Mitchell MS, Abrams J, Thompson JA, et al. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol 2007; 25:2078-2085 (Pubitemid 46972794)
25. Rousseau RF, Haight AE, Hirschmann-Jax C, et al. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood 2003; 101:1718-1726
26. Luketic L, Delanghe J, Sobol PT, Yang P, Frotten E, Mossman KL, Gauldie J, Bramson J, Wan Y. Antigen presentation by exosomes released from peptide-pulsed dendritic cells is not suppressed by the presence of active CTL. J Immunol 2007; 179:5024-5032
27. Montecalvo A, Shufesky WJ, Stolz DB, et al. Exosomes as a short-range mechanism to spread alloantigen between dendritic cells during T cell allorecognition. J Immunol 2008; 180:3081-3090
28. Zeelenberg IS, Ostrowski M, Krumeich S, et al. Targeting tumor antigens to secreted membrane vesicles in vivo induces efficient antitumor immune responses. Cancer Res 2008; 6812:28-35. (Pubitemid 351272243)
29. Napoletano C, Rughetti A, Agervig Tarp MP, et al. Tumor-associated Tn-MUC1 glycoform is internalized through the macrophage galactose-type C-type lectin and delivered to the HLA class I and II compartments in dendritic cells. Cancer Res 2007; 67:8358-8367
30. Hiltbold EM, Vlad AM, Ciborowski P, Watkins SC, Finn OJ. The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. J Immunol 2000; 165:3730-3741 (Pubitemid 32057279)
31. Shen L, Rock KL. Priming of T cells by exogenous antigen cross-presented on MHC class I molecules. Curr Opin Immunol 2006; 18:85-91. (Pubitemid 43049653)
32. Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 2008; 8:351-360